Boston Scientific Corp. (NYSE:BSX) has the first commercial implantations of Taxus Element in Europe under its belt, a month after winning CE Mark approval in the European Union.
The Natick, Mass.-based medical device maker said the first European use of the device occurred in Italy and the U.K. It’s the third iteration of the company’s Taxus paclitaxel-eluting platform, made of a platinum-chromium alloy using a new design.